Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
…, CM Wendtner, H Döhner, G Brittinger, B Emmerich… - Blood, 2006 - ashpublications.org
Combination chemotherapy with fludarabine plus cyclophosphamide (FC) was compared
with the standard regimen of fludarabine monotherapy in first-line treatment of younger …
with the standard regimen of fludarabine monotherapy in first-line treatment of younger …
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
…, G Brittinger, H Döhner, B Emmerich… - Blood, The Journal …, 2009 - ashpublications.org
Although chronic lymphocytic leukemia (CLL) is a disease of elderly patients, subjects older
than 65 years are heavily underrepresented in clinical trials. The German CLL study group (…
than 65 years are heavily underrepresented in clinical trials. The German CLL study group (…
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
…, S Serke, C Peschel, B Emmerich - Blood, The Journal …, 2001 - ashpublications.org
Rituximab (IDEC-C2B8) is a chimeric antibody that binds to the B-cell surface antigen CD20.
Rituximab has significant activity in follicular non-Hodgkin lymphomas. Much less is known …
Rituximab has significant activity in follicular non-Hodgkin lymphomas. Much less is known …
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia
…, I Kuhn-Hallek, E Thiel, B Emmerich - Blood, The Journal …, 1999 - ashpublications.org
Chronic lymphocytic leukemia (CLL) shows a remarkably heterogeneous clinical outcome;
survival ranges from several months in advanced stages to more than 10 years in early stages…
survival ranges from several months in advanced stages to more than 10 years in early stages…
Serum β2-Microglobulin and Serum Thymidine Kinase are Independent Predictors of Progression-Free Survival in Chronic Lymphocytic Leukemia and …
…, HD Schick, I Kuhn-Hallek, B Emmerich - Leukemia & …, 1996 - Taylor & Francis
Chronic lymphocytic leukemia (CLL) and immunocytoma (IC) are remarkably heterogeneous
with regard to their clinical course. The current staging systems can distinguish prognostic …
with regard to their clinical course. The current staging systems can distinguish prognostic …
Activation of Src Kinases p53/56lyn and p59hck by p210bcr/abl in Myeloid Cells
…, M Warmuth, BJ Druker, B Emmerich… - Cancer research, 1996 - AACR
Chronic myeloid leukemia is characterized by the Philadelphia (Ph 1 ) translocation t(9;22)
that generates a hybrid gene, bcr/abl, translated to a M r 210,000 tyrosine kinase (p210 bcr/…
that generates a hybrid gene, bcr/abl, translated to a M r 210,000 tyrosine kinase (p210 bcr/…
Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of the …
…, PR Jungblut, B Emmerich… - Blood, The Journal …, 2002 - ashpublications.org
Crystal-storing histiocytosis (CSH) is a rare event in disorders associated with monoclonal
gammopathy. The intracellular crystal formation is almost always accompanied by the …
gammopathy. The intracellular crystal formation is almost always accompanied by the …
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides
…, H Poeck, E Hartmann, R Jox, T Giese, B Emmerich… - Clinical cancer …, 2005 - AACR
Human B cells detect CpG motifs within microbial DNA via TLR9. Synthetic CpG
oligodeoxynucleotides are currently being tested in clinical trials for the therapy of different types of B …
oligodeoxynucleotides are currently being tested in clinical trials for the therapy of different types of B …
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
…, ME Goebeler, M Herold, B Emmerich… - …, 2005 - haematologica.org
BACKGROUND AND OBJECTIVES: Although bendamustine has been used for more than
30 years in the treatment of lymphoma, little is known about the optimal dosing schedule in …
30 years in the treatment of lymphoma, little is known about the optimal dosing schedule in …
The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion–mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and …
…, P Baumann, M Simsek, F Dayyani, B Emmerich… - Blood, 2004 - ashpublications.org
Primary drug resistance is a major problem in multiple myeloma, an incurable disease of the
bone marrow. Cell adhesion-mediated drug resistance (CAM-DR) causes strong primary …
bone marrow. Cell adhesion-mediated drug resistance (CAM-DR) causes strong primary …